Repatha vs Leqvio Side-Effect Profile: Evolocumab vs Inclisiran Head-to-Head

How These Two Drugs Lower PCSK9 Differently

Repatha and Leqvio reach the same therapeutic target through entirely different molecular mechanisms, and those mechanisms explain why their side-effect footprints look the way they do. Repatha is a monoclonal antibody that binds circulating PCSK9 protein in the bloodstream, blocking it from degrading LDL receptors on hepatocytes [1]. Leqvio works upstream. It is a double-stranded siRNA conjugated to N-acetylgalactosamine (GalNAc) that enters the hepatocyte and silences PCSK9 mRNA translation inside the cell [2].

This distinction matters for tolerability. Monoclonal antibodies can trigger immune-mediated injection-site reactions and, rarely, anti-drug antibody formation. siRNA-GalNAc conjugates concentrate in hepatocytes and provoke a localized inflammatory response at the injection site through a different pathway involving endosomal activation. The FOURIER trial (N=27,564) established evolocumab's safety profile over a median follow-up of 2.2 years [1]. The ORION-10 (N=1,561) and ORION-11 (N=1,617) trials did the same for inclisiran over 18 months of double-blind treatment [2]. No head-to-head randomized trial has directly compared their adverse-event rates, so all comparisons below are cross-trial observations that require the usual caveats about differing populations and protocols.

Injection-Site Reactions: The Most Visible Difference

The injection site is where these two drugs diverge most noticeably. In FOURIER, injection-site reactions occurred in 3.2% of evolocumab patients versus 3.0% of placebo patients, a difference that was not statistically significant [1]. The reactions were generally mild: erythema, bruising, or pain that resolved within days.

Inclisiran tells a different story. In pooled ORION-10 and ORION-11 data, injection-site reactions affected 8.2% of inclisiran patients versus 1.8% on placebo [2]. The most common presentation was erythema, followed by pain, induration, and pruritus. Most reactions were mild (72.8%) or moderate (24.5%), and nearly all resolved within one to two days. Only 0.2% of patients discontinued inclisiran because of injection-site issues [3].

Why the higher rate for Leqvio? The GalNAc-siRNA payload triggers a localized innate immune response as it is taken up by liver-tropic receptors present in dermal cells at the injection site. The reaction is self-limited and does not worsen with repeated dosing. In fact, ORION-8 open-label extension data through four years showed injection-site reaction rates that remained stable or declined over subsequent doses [4].

The American College of Cardiology's 2022 Expert Consensus Decision Pathway noted that "injection-site reactions with inclisiran, while more common than placebo, are predominantly mild and transient, and should not be a primary driver of drug selection" [5].

Musculoskeletal and Neurocognitive Adverse Events

Statin-treated patients are primed to worry about muscle symptoms. Both evolocumab and inclisiran perform reassuringly on this front. In FOURIER, myalgia occurred in 4.0% of evolocumab patients versus 4.1% on placebo [1]. ORION-10 reported back pain in 6.4% of inclisiran patients (6.2% placebo) and arthralgia in 5.0% (4.8% placebo) [2]. None of these differences reached significance.

Neurocognitive events drew intense scrutiny early in the PCSK9 era because of theoretical concerns about very low LDL-C concentrations and brain cholesterol metabolism. FOURIER included a prespecified neurocognitive substudy, EBBINGHAUS (N=1,974), which found no difference in cognitive function between evolocumab and placebo over a median of 19 months, even among patients achieving LDL-C levels below 25 mg/dL [6]. Dr. Robert Giugliano, the EBBINGHAUS principal investigator, stated: "There was no adverse effect of evolocumab on cognitive function, executive function, memory, or psychomotor speed, regardless of achieved LDL-C level" [6].

Inclisiran's ORION program reported neurocognitive adverse events at similar low rates in both active and placebo arms (1.2% vs 0.8% in ORION-10) [2]. The FDA label for inclisiran does not carry a neurocognitive warning.

Hepatic and Renal Safety

Both drugs show clean hepatic profiles. In FOURIER, alanine aminotransferase (ALT) elevations greater than three times the upper limit of normal occurred in 1.7% of evolocumab patients and 1.6% of placebo patients [1]. ORION-10 and ORION-11 reported ALT elevations above three times normal in 1.3% and 1.0% of inclisiran and placebo groups, respectively [2].

This is notable for inclisiran specifically because the siRNA mechanism concentrates the drug in hepatocytes. Pre-clinical work had flagged potential hepatotoxicity as a class concern for GalNAc-siRNA conjugates. The clinical data has not borne this out. Through four years of open-label follow-up in ORION-8, no hepatotoxicity signal emerged [4].

Renal safety data is similarly reassuring. Neither drug is renally cleared in a clinically significant way. FOURIER enrolled patients with eGFR as low as 20 mL/min/1.73 m² in subgroup analyses, and evolocumab's efficacy and safety were preserved across renal function strata [7]. Inclisiran's ORION-7 study specifically evaluated pharmacokinetics in patients with renal impairment and found no dose adjustment necessary for mild, moderate, or severe renal insufficiency [8].

Respiratory and Systemic Adverse Events

Upper respiratory tract infections and nasopharyngitis are commonly reported in both treatment groups. FOURIER documented nasopharyngitis in 10.5% of evolocumab patients (10.3% placebo) and upper respiratory infections in 7.0% (6.9% placebo) [1]. These rates are consistent with what appears in most large cardiovascular trials regardless of treatment assignment.

ORION-10 recorded nasopharyngitis in 7.4% of inclisiran patients (7.2% placebo) and bronchitis in 4.3% (3.8% placebo) [2]. Neither reached significance. The slightly lower absolute rates in the ORION program likely reflect shorter follow-up (18 months versus 2.2 years median in FOURIER) rather than a true safety advantage.

One systemic adverse event worth flagging: influenza-like illness was reported in 1.3% of inclisiran patients versus 0.6% on placebo in ORION-10 [2]. This aligns with the transient innate immune activation expected from siRNA therapeutics. The Endocrine Society's 2023 clinical practice guideline acknowledged that "siRNA-based PCSK9 inhibitors carry a distinct but manageable pattern of immune-mediated local reactions compared with monoclonal antibodies" [9].

Cardiovascular Outcomes and the Safety-Efficacy Link

Safety cannot be evaluated in isolation from efficacy. Repatha has completed cardiovascular outcome data. In FOURIER, evolocumab reduced the composite endpoint of cardiovascular death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina by 15% (HR 0.85 to 95% CI 0.79-0.92, P<0.001) over a median of 2.2 years [1]. No excess in cardiovascular death, cancer, or hemorrhagic stroke was observed.

Leqvio does not yet have completed cardiovascular outcome trial results. ORION-4 (N=15,000) is the ongoing CVOT comparing inclisiran with placebo in patients with atherosclerotic cardiovascular disease, with results anticipated in 2026 [10]. Until ORION-4 reports, inclisiran's regulatory approval rests on LDL-C reduction as a surrogate endpoint, supported by Mendelian randomization data showing that genetic PCSK9 loss-of-function variants confer proportional cardiovascular risk reduction [11].

This gap is relevant to side-effect discussions because long-term safety signals, particularly for rare events like hemorrhagic stroke or new-onset diabetes, require large populations followed over multiple years. Evolocumab has that dataset. Inclisiran does not, yet. Clinicians choosing between these agents should weigh the certainty of evolocumab's outcome data against inclisiran's dosing convenience.

Dosing Convenience and Its Impact on Adherence-Related Adverse Events

Repatha requires self-injection every two weeks (140 mg) or monthly (420 mg via autoinjector). Leqvio is administered as 284 mg subcutaneously by a healthcare professional at month 0, month 3, and every six months thereafter. The dosing schedule is not traditionally categorized as a "side effect," but it directly influences adherence, and non-adherence to lipid-lowering therapy is itself a cardiovascular risk factor.

Real-world data from a 2023 retrospective cohort study published in the Journal of the American Heart Association found that 12-month persistence with PCSK9 monoclonal antibodies was 55.2% in a commercially insured U.S. population [12]. Inclisiran's in-office administration model is designed to bypass the adherence problem entirely. ORION-8 reported that 93.7% of scheduled injections were received over four years of open-label follow-up [4].

The tradeoff: patients on Leqvio cannot self-administer at home, which creates a logistical burden of office visits twice yearly. For patients with limited mobility or rural access, this could be a meaningful barrier. Repatha's home-administration model offers autonomy but places the adherence responsibility on the patient.

Anti-Drug Antibody Formation

As a monoclonal antibody, evolocumab carries theoretical risk of anti-drug antibody (ADA) development. In FOURIER, binding antibodies were detected in 0.3% of evolocumab-treated patients, and neutralizing antibodies were extremely rare with no clinical impact on efficacy or safety [1].

Inclisiran is not a protein and does not trigger classical ADA responses. However, pre-existing antibodies to the GalNAc conjugate linker have been detected in small percentages of patients. In ORION-10, these had no effect on pharmacokinetics or LDL-C lowering [2]. The practical implication: neither drug has a meaningful immunogenicity problem.

Special Populations: Diabetes, Elderly, and Familial Hypercholesterolemia

Both agents have been studied in patients with type 2 diabetes. A prespecified FOURIER analysis of 11,031 diabetic patients found that evolocumab reduced LDL-C and major vascular events without increasing new-onset diabetes (HR 1.05 to 95% CI 0.94-1.17) or worsening glycemic control [13]. ORION-10 included 32% of participants with diabetes, and subgroup analysis showed consistent LDL-C reduction without HbA1c changes [2].

In patients aged 75 and older, FOURIER subgroup data showed consistent efficacy and no excess adverse events with evolocumab [1]. ORION-11 enrolled patients up to age 80, with adverse-event rates comparable across age strata [2].

For heterozygous familial hypercholesterolemia (HeFH), both drugs are approved. Evolocumab has additional approval for homozygous FH based on the TESLA Part B and TAUSSIG studies, where higher doses (420 mg monthly) showed manageable safety [14]. Inclisiran received HeFH indication from ORION-9 (N=482), which showed a 39.7% placebo-adjusted LDL-C reduction with a safety profile consistent with ORION-10/11 [15].

Which Drug Has Fewer Side Effects Overall?

A direct answer: both drugs are well tolerated, and serious adverse-event rates are comparable to placebo in their respective trials. The differences are minor. Leqvio produces more injection-site reactions (8.2% vs 3.2%) but requires only two injections per year. Repatha produces fewer local reactions per injection but requires 12 to 26 injections annually. When calculated on a per-year basis, the total injection-site reaction burden may be similar.

The 2022 ACC Expert Consensus Decision Pathway recommended individualized selection based on patient preference, access to healthcare visits, insurance coverage, and the value placed on cardiovascular outcome data [5]. Neither drug has shown serious hepatic, renal, neurocognitive, or musculoskeletal toxicity beyond placebo rates in controlled trials.

For patients who want proven cardiovascular risk reduction with long-term safety data, evolocumab has the stronger evidence base today. For patients who struggle with self-injection adherence and prefer twice-yearly office visits, inclisiran offers a tolerability profile that may produce better real-world outcomes through sustained LDL-C lowering. The first in-office Leqvio injection should include a 15-minute post-injection observation period per the prescribing information, particularly for monitoring injection-site reactions [3].